Eton Pharmaceuticals IncChange company Symbol lookupSelect an option...ETON Eton Pharmaceuticals IncAHI Advanced Health Intelligence LtdOTLK Outlook Therapeutics IncPBHC Pathfinder Bancorp Inc (MARYLAND)CMA Comerica IncIART Integra Lifesciences Holdings CorpARKW.SO ARK Next Generation Internet ETFAGNC Agnc Investment CorpHCA HCA Healthcare IncLGHL Lion Group Holding LtdGo
Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 3.46x
- Price/Book (MRQ)
- 5.98x
- Price/Cash Flow (TTM)
- 169.72x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Norbert G. Riedel
- Sean E. BrynjelsenPres.
- James R. GruberCFO
- David C. KrempaOther
- Jennifer Adams
Address
- 21925 W Field Pkwy Ste 235
- Deer Park, IL 60010-7278
- Phone: (847) 787-7361
- https://etonpharma.com/
Insider Trading
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.